Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy

Figures & data

Table 1 Clinicopathological characteristics of the 242 study patients

Age, years
Median (range)	71.0 (42–83)
Sex, n (%)
Male	126 (52)
Female	116 (48)
Body mass index, kg/m^2
Median (IQR)	25.10 (13–37)
Primary tumor location, n (%)
Renal pelvis	152 (63)
Ureteral	90 (37)
Surgical approach, n (%)
Open	162 (63)
Laparoscopic	80 (22)
Tumor histology, n (%)
Papillary	17 (6.9)
Infiltrating	225 (93.1)
pT stage, n (%)
pTa-pTis-pT1	65 (26.8)
pT2	43 (17.8)
pT3	87 (36.1)
pT4	47 (19.3)
Lymph node status, n (%)
pN0	212 (87.7)
pN+	30 (12.3)
M stage, n (%)
pM0	232 (96.0)
pM1	10 (4.0)
Contralateral kidney size, cm
Length, median (range)	10.16 (7.0–12.8)
Width, median (range)	5.1 (3.8–6.9)
Thickness, median (range)	2.0 (1.2–2.3)

Abbreviations: IQR, interquartile range; M stage, metastasis stage; pT stage, primary tumor stage.

Table 2 Clinicopathological characteristics of 102 patients who met the eligibility cutoff of 60 mL/min/1.73 m² for cisplatin-based chemotherapy

Characteristics	Total (n=102)	(n=37) eGFR ≧60 mL/min	(n=65) eGFR <60 mL/min	Sig	OR	95% CI for OR
Age (years), mean ± SD	65.82±10.9	63.0±13.2	67.43±9.02	0.001	1.068	1.027	1.112
Sex, n
Male	57	26	31	0.029	2.592	1.101	6.103
Female	45	11	34
BMI (kg/m^2), mean ± SD	24.7±4.5	21.56±4.79	26.47±3.25	<0.001	1.581	1.261	1.981
Preoperative Scr (mg/dL), mean ± SD	0.99±0.16	0.96±0.19	1.00±0.15	0.236	4.645	0.366	58.984
Preoperative eGFR (mL/min/1.73 m^2), mean ± SD	71.97±11.3	79.78±13.5	68.84±6.7	<0.001	0.892	0.845	0.942
History of diabetes, n
Yes	22	6	16	0.325	1.687	0.596	4.776
No	80	31	49
History of HT, n
Yes	33	6	27	0.011	3.671	1.345	10.017
No	69	31	38
Tumor characteristics
Tumor histology, n
Papillary	6	4	2	0.133	3.818	0.664	21.947
Infiltrating	96	33	63
Tumor side, n
Left	74	21	30	0.304	0.653	0.29	1.472
Right	71	16	35
Tumor stage, n
T1+Ta	23	8	15	0.741	0.938	0.641	1.372
T2	20	4	16
T3	33	16	17
T4	26	9	17
Node status, n
N0	91	30	61	0.056	0.281	0.076	1.035
N+	11	7	4
Contralateral kidney size (cm), mean ± SD
Length	10.50±1.1	11.21±0.89	10.1±1.0	<0.001	0.342	0.212	0.553
Width	5.13±1.12	5.59±0.7	4.86±1.24	0.003	0.448	0.265	0.756
Thickness	0.71±0.09	0.75±0.08	0.69±0.09	0.002	0	0	0.05
Hydronephrosis, n
Yes	77	34	43	0.007	0.172	0.048	0.625
No	25	3	22

Abbreviations: BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HT, hypertension; OR, odds ratio; Scr, serum creatinine level; SD, standard deviation; Sig, P-value.

Table 3 Clinicopathological characteristics of 145 patients who met the eligibility cutoff of 45 mL/min/1.73 m² for cisplatin-based chemotherapy

Characteristics	Total (n=145)	(n=102) eGFR ≧45 mL/min	(n=43) eGFR <45 mL/min	Sig	OR	95% CI for OR
Age (years), mean ± SD	66.9±10.1	66.82±10.8	68.0±10.0	0.754	1.006	0.971	1.042
Sex, n
Male	74 (51.0)	47 (67.1)	27	0.068	0.506	0.244	1.052
Female	71 (49.0)	55 (66.2)	16
BMI, kg/m^2, mean ± SD	24.51±4.54	23.48±4.40	26.97±3.90	<0.001	1.243	1.111	1.391
Scr, mg/dL, mean ± SD	1.06±0.193	1.00±0.166	1.19±0.19	<0.001	493.082	36.913	6,586.62
eGFR, mL/min, mean ± SD	66.59±13.5	69.59±14.0	59.48±8.83	<0.001	0.927	0.892	0.962
History of diabetes, n
Yes	35	28	7	0.156	0.514	0.205	1.288
No	110	74	36
History of HT, n
Yes	61	45	16	0.442	0.751	0.361	1.56
No	84	57	27
Tumor characteristics
Tumor histology, n
Papillary	10	6	4	0.462	0.609	0.163	2.278
Infiltrating	135	96	39
Tumor side, n
Left	74	51	23	0.701	1.15	0.563	2.348
Right	71	51	20
Tumor stage, n
T1+Ta	38	14	24	<0.001	0.335	0.222	0.505
T2	25	20	5
T3	48	34	14
T4	34	34	0
Node status, n
N0	134	95	39	0.614	1.392	0.386	5.025
N+	11	7	4
Contralateral kidney size (cm), mean ± SD
Length	10.42±0.99	10.6±1.06	9.9±0.56	<0.001	0.399	0.241	0.66
Width	5.12±1.00	5.4±0.82	4.57±1.17	<0.001	0.386	0.229	0.651
Thickness	0.70±0.09	0.73±0.09	0.64±0.76	<0.001	0.001	0	0.002
Hydronephrosis, n
Yes	107	83	24	0.002	0.289	0.132	0.632
No	38	19	19

Abbreviations: BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HT, hypertension; OR, odds ratio; Scr, serum creatinine level; SD, standard deviation; Sig, P-value.

Table 4 Multivariate analysis of preoperative variables for disease-specific survival

	P-value	OR	(95% CI for OR)
Post-eGFR<60
Age	0.007	1.987	1.204	3.279
BMI	0.005	10.392	2.046	52.788
Preoperative eGFR	0.002	0.554	0.385	0.798
Contralateral renal length	0.012	0.012	0.000	0.386
Hydronephrosis	0.011	0.000	0.000	0.065
Post-eGFR<45
BMI	<0.001	1.493259	1.243	1.793
Preoperative eGFR	<0.001	0.8396842	0.769	0.916
Contralateral renal length	0.064	0.346669	0.113	1.063
Contralateral renal width	0.010	0.3749981	0.178	0.788
Contralateral renal thickness	0.055	0.1191959	0.014	1.050
Hydronephrosis	<0.001	0.0476294	0.010	0.235

Abbreviations: BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.